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Editorial
The Zika virus (ZIKV) has been an uncommon zoonotic virus since
it was discovered in Uganda in 1947. It has been associated to a large
impact into the equatorial region of Africa by infecting primates while
causing sporadic mild infections in humans [1]. Nonetheless, over the
last few years, a combination of factors such as increased populations
of Aedes mosquito vectors, changes in codon usage and immune
enhancement associated to previous flavovirus epidemics, e.g., Dengue
[2], has led to an explosive propagation of ZIKV to Southeast Asia
(2013-14) and South-Central America (2015).
Even though ZIKV generally causes a mild or asymptomatic disease,
pandemic infections in these areas yield to a 20-fold increase in the
number of cases of microcephaly in newborns as well as to
concomitant epidemics of Guillian-Barré Syndrome and other
neurologic conditions. As a consequence, a public health emergency of
international concern was declared by the World Health Organization
(WHO) in February 2016.
However, a direct causal relationship remains to be experimentally
established. Recent reports of mother-fetus and sexual transmission
together with the possibility that ZIKV adapts to be transmitted by
more widely-spread and efficient vectors, are further causes for
concern.
The current rate of spread ZIKV has drawn increasing attention
from worldwide scientific community for developing candidate
vaccines by investigating murine models and viral pathogenesis [3-5].
In spite of such efforts, there is neither a vaccine nor a specific antiviral
therapy for the prevention or treatment of infections by ZIKV, though
recent studies have demonstrated antiviral activity when 2´-C-
methylated nucleosides were tested [6]. The viral polymerase inhibitor
7-deaza-2´-C-methyladenosine (7DMA) has been identified as a
potent ZIKV inhibitor in a ZIKV infection model in mice [5].
These in vitro cellular assays could allow to screen for and validate
novel inhibitors of ZIKV replication. The final solution will clearly
require a joint work in an interdisciplinary environment. In that
framework, we are positive that computational chemistry field would
be able to significantly contribute into both identifying molecular
targets and designing drugs with improved properties. This Editorial
briefly touches the main techniques that might be applied to help to
resolve this healthcare crisis.
Advanced computational drug screening (the so called Virtual
Screening techniques, or VS) such as docking techniques will play an
important role in the discovery of novel bioactive compounds in the
context of ZIKV. The available crystal structures from parts of the virus
and new homology models might be already used as an early state of a
computational protocol. More advanced docking techniques, including
Blind Docking simulations could be subsequently applied to process
large databases of compound libraries [7-11]. Ligand-based virtual
screening (LBVS) methods might be also helpful in the search of new
drugs against ZIKV since their performance does not depend directly
on the availability of crystallographic structures of the protein targets.
Indeed, recent studies have also applied LBVS to find potential
inhibitors against viruses [12].
The above-mentioned techniques have been shown to provide first
valuable description of a wide panel of problems of biological interest,
with a largely favourable quality/computational cost rate. However, as
any simulation protocol, such approaches have an inherent limitation:
their resolution is not accurate enough to delineate the main drug-
target chemical contacts during the binding process. More refined
techniques that account for the electronic description of the biological
processes, e.g., molecular dynamics (MD) and quantum mechanical
(QM) calculations, could be used to further refine the structures while
simultaneously leading to more precise interaction energies.
However, we would like to point out the possibility of using
alternative approaches others than molecular modeling based
methods. For instance, advanced machine learning methods (i.e. deep
learning) are suitable techniques to capture complex statistical patterns
between thousands of descriptors extracted from drug compounds. As
recently demonstrated by Ma and co-workers [13], deep neural
networks (DNN) can routinely make better prospective predictions
than other standard machine learning methods on Kaggle competition
data sets. In addition, Hughes et al. [14] built a deep machine learning
network in order to identify the site of epoxidation and to separate
epoxidized and non-epoxidized molecules, just to name two relevant
examples.
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In view of the different and interesting approaches that are ready for
discovering novel compounds in the context of the Zika virus, we
foresee that nanomolar inhibitors could be discovered in coming few
years. This knowledge will open up the expansion towards enhanced
therapeutic approaches in the eradication of the ZIKV. It is worth
ending this Editorial by highlighting a very recent contribution by
Ekins and co-workers [15].
As stated by these authors, no crystal structures of ZIKV targets
have been deposited in public databases such as PDB, ChEMBL and
PubChem, which is certainly a major handicap to the application of
computational techniques.
However, homology models for 15 proteins involved in ZIKV
disease are freely accessible since March 2016, including NS5, FtsJ,
NS4B, NS4A, HELICc, DEXDc, peptidase S7, NS2B, NS2A, NS1, E
stem, glycoprotein M, propeptide, capsid and glycoprotein E [16].
Ekins and co-workers propose to use such models as starting point for
a open drug discovery effort.
We fully agree with this collaborative strategy, which will require the
use of High Performance Computing architectures such as
Supercomputers and GPUs [17-19] aiming at combining some, or even
all of the discussed techniques herein (LBVS, Docking, MD, QM) with
the final goal of beating ZIKV together.
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